News related to Revlimid (Lenalidomide) and/or conditions it is approved for
Lenalidomide Approved for Myeloma Maintenance After HSCT
Source: Medscape Hematology-Oncology Headlines [2017.02.23]
Lenalidomide (Revlimid) gets the first-ever FDA approval for use in myeloma as a maintenance therapy after autologous stem cell transplant.
Inhibition of EZH2 might be new therapy of multiple myeloma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2017.01.13]
In a study published in the scientific journal Oncotarget, researchers from Uppsala University show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2...
Additions to standard multiple myeloma therapy do not appear to yield additional benefit
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.08]
Largest randomized trial finds second round of chemotherapy or stem cell transplant does not improve progression-free survival.
Advances in multiple myeloma, lymphoma and other hematologic malignancies presented at ASH
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.07]
Researchers from University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine presented significant new research findings in multiple myeloma, lymphoma and...
Source: MedicineNet Amyloidosis Specialty [2016.09.22]
Title: Multiple Myeloma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/22/2016 12:00:00 AM
Less frequent dosing of drug for patients with bone metastases does not increase risk of fracture, other bone-related events
Source: Bones / Orthopedics News From Medical News Today [2017.01.05]
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, use of the bisphosphonate drug zoledronic acid every 12 weeks compared with the standard dosing...
Aggressive form of leukaemia linked to defective 'protein factory'
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.14]
20 to 40 percent of the patients with multiple myeloma - a type of leukaemia - have a defect in the ribosome, the protein factory of the cell.